Rhesonativ: Uses, Dosage & Side Effects
Human anti-D immunoglobulin for preventing Rh immunization in Rh-negative women during pregnancy, delivery, and after sensitizing events
Rhesonativ is a human anti-D immunoglobulin used to prevent Rh immunization (sensitization) in Rh(D)-negative women. When an Rh-negative mother carries an Rh-positive baby, fetal red blood cells can enter the maternal circulation and trigger the production of anti-D antibodies. These antibodies can cross the placenta and attack fetal red blood cells in subsequent pregnancies, causing hemolytic disease of the fetus and newborn (HDFN). Rhesonativ prevents this by neutralizing Rh-positive fetal cells before the mother's immune system responds.
Quick Facts: Rhesonativ
Key Takeaways
- Rhesonativ prevents Rh immunization in Rh-negative women exposed to Rh-positive blood, protecting current and future pregnancies from hemolytic disease of the newborn.
- The injection must be given within 72 hours of delivery or a sensitizing event for maximum effectiveness, though some benefit may exist up to 10 days afterward.
- Rhesonativ is administered by intramuscular injection by a healthcare professional and is not suitable for self-administration at home.
- Common side effects are mild and include injection site reactions, headache, and low-grade fever; serious allergic reactions are very rare.
- Live vaccines (measles, mumps, rubella, varicella) should be delayed for at least 3 months after Rhesonativ administration due to potential reduced efficacy.
What Is Rhesonativ and What Is It Used For?
Rhesonativ contains antibodies directed against the Rhesus D (Rh D) antigen, a protein found on the surface of red blood cells in approximately 85% of the population (Rh-positive individuals). When a woman who lacks this protein (Rh-negative) becomes pregnant with a baby who is Rh-positive, there is a risk that fetal blood cells will cross the placenta and enter the mother's circulation, particularly during delivery, miscarriage, or invasive procedures.
If this occurs without prophylaxis, the mother's immune system may recognize the Rh D antigen as foreign and produce anti-D antibodies. This process, known as Rh immunization or Rh sensitization, poses no immediate threat to the mother. However, in subsequent pregnancies with an Rh-positive baby, these maternal antibodies can cross the placenta and attack the fetal red blood cells, leading to hemolytic disease of the fetus and newborn (HDFN). HDFN can range in severity from mild anemia and jaundice to severe hydrops fetalis (fluid accumulation in fetal tissues) and intrauterine death.
The introduction of anti-D immunoglobulin prophylaxis in the 1960s and 1970s is considered one of the greatest achievements in obstetric medicine. Before its availability, Rh immunization affected approximately 14% of Rh-negative women after their first Rh-incompatible pregnancy. With proper anti-D prophylaxis, this rate has been reduced to less than 0.1-0.2%, according to data from the World Health Organization and major obstetric organizations worldwide.
Indications
Rhesonativ is indicated for use in Rh(D)-negative women in the following clinical situations:
- Routine antenatal prophylaxis: Administered at approximately 28-30 weeks of gestation to prevent sensitization during the third trimester, when the risk of fetal-maternal hemorrhage increases.
- Postpartum prophylaxis: Given within 72 hours of delivery when the newborn is confirmed as Rh(D)-positive.
- After miscarriage or threatened miscarriage: To prevent sensitization from any fetal-maternal hemorrhage that may have occurred.
- After ectopic (tubal) pregnancy: Fetal cells may enter the maternal circulation even in ectopic pregnancies.
- After invasive prenatal procedures: Including amniocentesis, chorionic villus sampling (CVS), cordocentesis (fetal blood sampling), and external cephalic version (manual turning of a breech baby).
- After abdominal trauma during pregnancy: Any event that may cause mixing of fetal and maternal blood.
- After intrauterine fetal death: In the late stages of pregnancy.
- Incompatible blood transfusion: Rhesonativ can also be used in Rh-negative individuals who have accidentally received an Rh-positive blood transfusion.
What Should You Know Before Receiving Rhesonativ?
Contraindications
Rhesonativ must not be used if you have a known allergy (hypersensitivity) to human immunoglobulin or to any of the other ingredients in the product. The medication is specifically designed for Rh(D)-negative individuals and should not be administered to Rh(D)-positive persons or to individuals who have already developed anti-D antibodies (i.e., those who are already Rh-immunized), as the product would provide no benefit in these cases.
Before receiving Rhesonativ, inform your healthcare provider of your complete medical history, including any previous reactions to blood products or immunoglobulin preparations. Your Rh blood type must be confirmed by laboratory testing before the medication is administered.
Warnings and Precautions
If you experience symptoms such as shortness of breath, pain and swelling in a limb, or chest pain after receiving Rhesonativ, contact your healthcare provider immediately, as these may be signs of a blood clot (thrombosis). Although rare, thromboembolic events have been reported with immunoglobulin products.
Virus Safety
When medicines are manufactured from human blood or plasma, special measures are taken to prevent infections from being transmitted to patients. These measures include:
- Careful selection and screening of blood and plasma donors to ensure that those at risk of carrying infections are excluded
- Testing of individual donations and plasma pools for signs of viruses and infections
- Inclusion of processing steps that can inactivate or remove viruses during manufacturing
Despite these measures, the risk of transmitting infection cannot be completely eliminated when medicines made from human blood or plasma are administered. However, the safety measures are considered effective against enveloped viruses such as HIV, hepatitis B, and hepatitis C, as well as against the non-enveloped hepatitis A virus. The measures may be of limited value against non-enveloped viruses such as parvovirus B19. Immunoglobulin products have not been associated with hepatitis A or parvovirus B19 infections, likely because the antibodies naturally present in the product provide protective benefit.
Your healthcare provider will record the product name and batch number each time Rhesonativ is administered to enable traceability.
Pregnancy and Breastfeeding
Rhesonativ is specifically designed for use during pregnancy and can be used safely during breastfeeding. The medication is the standard of care for Rh-negative women during the perinatal period. Anti-D antibodies may be present in breast milk in small quantities, but this is not considered harmful to the nursing infant. There is no need to interrupt breastfeeding after receiving Rhesonativ. International guidelines from ACOG, RCOG, and WHO all support its use in breastfeeding mothers.
Driving and Operating Machinery
No effects on the ability to drive or operate machinery have been observed with Rhesonativ.
How Does Rhesonativ Interact with Other Drugs?
Rhesonativ can reduce the effectiveness of certain live attenuated vaccines. This occurs because the passively administered antibodies in the immunoglobulin can neutralize the weakened virus in the vaccine before the immune system has time to mount its own response. This interaction is clinically significant for vaccines against measles, mumps, rubella (MMR), and varicella (chickenpox).
The interaction works in both directions: if you received one of these live vaccines within approximately 2-4 weeks before an injection of anti-D immunoglobulin, the vaccine's effectiveness may be compromised. Similarly, after treatment with Rhesonativ, you should wait at least 3 months before receiving any of these live vaccines. It is therefore important that the healthcare provider administering your vaccinations is aware of any recent or planned treatment with Rhesonativ.
Inform your doctor if you are taking any blood tests, as treatment with immunoglobulin products can affect the results of certain serological tests. Anti-D antibodies present in the product may lead to false-positive results in antibody screening tests (such as the indirect Coombs test).
| Interacting Substance | Severity | Effect | Recommendation |
|---|---|---|---|
| MMR Vaccine (measles, mumps, rubella) | Major | Reduced vaccine effectiveness due to passive antibody interference | Wait at least 3 months after Rhesonativ before vaccinating |
| Varicella (chickenpox) Vaccine | Major | Reduced vaccine effectiveness due to passive antibody interference | Wait at least 3 months after Rhesonativ before vaccinating |
| Other Live Attenuated Vaccines | Moderate | Potential reduction in vaccine immune response | Discuss timing with healthcare provider |
| Inactivated Vaccines (influenza, tetanus, etc.) | None | No clinically significant interaction | Can be given concurrently |
| Serological Blood Tests (Coombs test) | Moderate | May cause false-positive results in antibody screening | Inform laboratory of recent anti-D administration |
What Is the Correct Dosage of Rhesonativ?
Rhesonativ is always administered by a healthcare professional. The dose and timing depend on the specific clinical indication. Your doctor will determine the appropriate dose based on established guidelines and the individual clinical situation. The injection is given intramuscularly (into a muscle), typically in the deltoid or gluteal region.
Before injection, the healthcare provider will aspirate (pull back on the syringe plunger) to ensure the needle is not in a blood vessel. If there is a coagulation disorder that makes intramuscular injection inadvisable, Rhesonativ may be given subcutaneously (under the skin) if an intravenous product is not available. A compress should be applied gently to the injection site after administration.
If a large volume is required (more than 2 mL for children or more than 5 mL for adults), it is recommended to divide the dose into multiple injections at different sites. Rhesonativ must not be mixed with other medicines.
| Indication | Typical Dose | Timing | Notes |
|---|---|---|---|
| Routine antenatal prophylaxis | 625-1500 IU (125-300 mcg) | At 28-30 weeks gestation | May vary by national guidelines |
| Postpartum prophylaxis | 1000-1500 IU (200-300 mcg) | Within 72 hours of delivery | When baby is confirmed Rh-positive |
| Miscarriage / threatened miscarriage (up to 12 weeks) | 625 IU (125 mcg) | As soon as possible | Minimum effective dose |
| Miscarriage / ectopic pregnancy (after 12 weeks) | 1000-1500 IU (200-300 mcg) | As soon as possible | Larger dose due to greater fetal blood volume |
| Amniocentesis / CVS / cordocentesis | 625-1500 IU (125-300 mcg) | At time of procedure | Dose depends on gestational age |
| Large fetal-maternal hemorrhage | 100 IU (20 mcg) per mL fetal blood | As soon as possible | Based on Kleihauer-Betke test results |
| Incompatible blood transfusion | 100 IU (20 mcg) per mL Rh-positive blood | As soon as possible | IV anti-D may be preferred for large volumes |
Children
There are no specific data on the use of Rhesonativ in children. However, anti-D immunoglobulin may be required in Rh-negative female children or adolescents who experience trauma or receive an incompatible blood transfusion. Dosing in such cases should be determined by the treating physician based on clinical guidelines.
Missed Dose
Since Rhesonativ is administered by healthcare professionals in clinical settings, a missed dose is uncommon. However, if the standard 72-hour window after delivery or a sensitizing event is exceeded, anti-D immunoglobulin may still provide some benefit if given within up to 10 days. Beyond this period, the medication's protective effect is uncertain, but some guidelines recommend administration up to 13 days post-event. Consult your doctor immediately if you believe a dose may have been missed.
Overdose
There is no specific antidote for overdose of anti-D immunoglobulin. Since Rhesonativ is administered by healthcare professionals in controlled clinical settings, overdose is unlikely. In the event that a dose significantly exceeding recommendations is given, the patient should be monitored for signs of hemolysis (destruction of red blood cells), including fatigue, dark urine, and jaundice. Blood counts and kidney function tests may be performed as a precaution. No life-threatening consequences from overdose with anti-D immunoglobulin have been reported in the medical literature.
What Are the Side Effects of Rhesonativ?
Like all medicines, Rhesonativ can cause side effects, although not everybody gets them. Most side effects associated with anti-D immunoglobulin are mild and transient, resolving on their own within a few days. The following side effects have been reported with Rhesonativ, though the exact frequency cannot be established from available data:
Reported Side Effects
Frequency not known (cannot be estimated from available data)
- Headache
- Rapid heartbeat (palpitations)
- Low blood pressure (hypotension)
- Wheezing
- Nausea and vomiting
- Skin reactions (rash, itching, hives)
- Joint pain (arthralgia)
- Lower back pain
- Dizziness
- Fever
- General feeling of discomfort (malaise), including chest discomfort
- Chills
- Injection site reactions (swelling, pain, redness)
Rare but Serious
Very rare (<1/10,000)
- Hemolysis (destruction of red blood cells)
- Severe allergic reactions (anaphylaxis), including anaphylactic shock
The overall safety profile of Rhesonativ is favorable, and most women receive the injection without experiencing any side effects beyond mild, transient discomfort at the injection site. Anti-D immunoglobulin has been used routinely worldwide for over 50 years with an excellent safety record, as documented in extensive post-marketing surveillance data and reviews by the European Medicines Agency (EMA) and national regulatory authorities.
If you experience any side effects, including those not mentioned above, inform your healthcare provider. Reporting side effects helps increase the available information on the safety of medicines.
How Should You Store Rhesonativ?
Proper storage of Rhesonativ is essential to maintain its efficacy and safety. The product should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F to 46°F). Do not freeze Rhesonativ, as freezing will damage the immunoglobulin proteins and render the product ineffective. The ampoule should be kept in the outer carton at all times to protect the solution from light exposure.
During the shelf life, the product may be stored at room temperature (below 25°C / 77°F) for a single period of up to 1 month without being returned to refrigeration. If it has been kept at room temperature for more than 1 month, the product must be discarded. Once removed from refrigeration, mark the carton with the date to track the allowable room temperature storage period.
The product should not be used after the expiry date stated on the label and carton. The expiry date refers to the last day of the stated month. The solution should appear colorless to pale yellow or light brown. Do not use Rhesonativ if the solution is cloudy or contains particles or precipitates. The contents of an opened ampoule must be used immediately; any remaining solution should be discarded.
Keep Rhesonativ out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste. Consult your pharmacist about proper disposal of medicines that are no longer needed, as these measures help protect the environment.
What Does Rhesonativ Contain?
Active Substance
The active ingredient is human anti-D immunoglobulin. Each milliliter contains 625 IU (125 micrograms) of human anti-D immunoglobulin. The product is available in two presentations:
- 1 mL ampoule: Contains 625 IU (125 micrograms) of human anti-D immunoglobulin
- 2 mL ampoule: Contains 1250 IU (250 micrograms) of human anti-D immunoglobulin
The total human protein content is 165 mg per milliliter, of which at least 95% is immunoglobulin G (IgG). The anti-D antibodies in the product are derived from the plasma of carefully screened human donors who have been immunized against the Rh D antigen.
Inactive Ingredients (Excipients)
| Ingredient | Function |
|---|---|
| Glycine | Stabilizer – protects the immunoglobulin during storage |
| Sodium chloride | Tonicity agent – ensures the solution is isotonic |
| Sodium acetate | Buffer – maintains the correct pH |
| Polysorbate 80 | Surfactant – helps prevent protein aggregation |
| Water for injections | Solvent |
Available Pack Sizes
Rhesonativ is available in the following pack sizes: 1 × 1 mL ampoule, 1 × 2 mL ampoule, and 10 × 2 mL ampoules. Not all pack sizes may be marketed in every country. The color of the solution may vary from colorless to pale yellow or light brown. This is a normal variation and does not affect the quality or efficacy of the product.
Rhesonativ is manufactured by Octapharma AB, Stockholm, Sweden. The product is approved and marketed across the European Economic Area under the brand name Rhesonativ in multiple countries.
Frequently Asked Questions About Rhesonativ
Rh incompatibility occurs when an Rh-negative mother carries an Rh-positive baby. The Rh factor is a protein on the surface of red blood cells inherited from parents. About 15% of the Caucasian population is Rh-negative. During pregnancy or delivery, small amounts of the baby's blood may enter the mother's bloodstream. If the baby is Rh-positive, the mother's immune system may recognize the Rh protein as foreign and produce antibodies against it. These antibodies can cross the placenta in future pregnancies and attack the baby's red blood cells, causing hemolytic disease of the newborn (HDN), which can range from mild jaundice to severe anemia and even fetal death.
Anti-D immunoglobulin prophylaxis, including Rhesonativ, is highly effective. Before the introduction of anti-D prophylaxis in the late 1960s, Rh immunization occurred in approximately 14% of Rh-negative women after an Rh-incompatible pregnancy. With proper prophylaxis, the sensitization rate has been reduced to approximately 0.1-0.2%. When both antenatal prophylaxis (at 28 weeks) and postpartum prophylaxis (within 72 hours of delivery) are provided, the protection rate exceeds 99%. This makes anti-D immunoglobulin one of the most successful preventive interventions in obstetric medicine.
While the standard recommendation is to administer anti-D immunoglobulin within 72 hours of a sensitizing event, there is evidence that some protective benefit may be gained if the injection is given within up to 10 days. Some national guidelines extend this window to 13 days. However, the effectiveness decreases the longer the delay, as the mother's immune system may have already begun producing its own anti-D antibodies. If you believe a dose may have been missed or delayed, contact your healthcare provider as soon as possible, as any protection is better than none.
Yes. If you are Rh-negative, you will need anti-D immunoglobulin prophylaxis with every pregnancy, regardless of whether you received it in previous pregnancies. The protection provided by Rhesonativ is temporary, lasting only a few weeks to months. Each new pregnancy presents a new risk of sensitization. Your Rh blood type and antibody status will be checked early in each pregnancy to guide management. If testing shows that you have already developed anti-D antibodies from a previous exposure, prophylaxis with Rhesonativ will no longer be effective and is not indicated.
If both parents are confirmed Rh-negative, the baby will also be Rh-negative, and there is no risk of Rh immunization. In this case, anti-D immunoglobulin is not necessary. However, paternity must be certain, and the father's Rh status must be confirmed by reliable laboratory testing. In some healthcare systems, non-invasive prenatal testing (NIPT) of fetal Rh type from maternal blood (cell-free fetal DNA) is now available, allowing targeted prophylaxis only when the fetus is confirmed Rh-positive. If fetal Rh status cannot be determined, prophylaxis is given as a precaution.
Yes, Rhesonativ is safe for the baby. The anti-D antibodies in Rhesonativ are given specifically to protect the baby in the current and future pregnancies. While a small amount of anti-D antibody may cross the placenta, the levels are far too low to cause significant hemolysis in the fetus. In contrast, if Rh immunization occurs without prophylaxis, the mother's own immune-generated anti-D antibodies can reach much higher levels and cause severe hemolytic disease. The benefit of Rhesonativ in preventing HDFN far outweighs any theoretical risks to the fetus. Decades of clinical use and extensive safety data support its use.
References
- European Medicines Agency (EMA). Rhesonativ – Summary of Product Characteristics. Last updated 2022. Available from EMA product database.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstetrics & Gynecology. 2023;141(1):e1-e14.
- Royal College of Obstetricians and Gynaecologists (RCOG). The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis. Green-top Guideline No. 22. London: RCOG; 2021.
- World Health Organization (WHO). WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience. Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management. NICE Guideline NG126. Updated 2023.
- Qureshi H, Massey E, Kirwan D, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfusion Medicine. 2014;24(1):8-20.
- Bennardello F, Coluzzi S, Curciarello G, et al. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfusion. 2015;13(1):109-134.
- Cortey A, Brossard Y, Beliard R, et al. Prevention of fetomaternal rhesus-D allo-immunization. Literature review. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction. 2006;35(Suppl 1):1S87-1S122.
- de Haas M, Thurik FF, van der Ploeg CPB, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ. 2016;355:i5789.
- Tiblad E, Westgren M, Reilly M, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation – outcome of a new antenatal screening and prevention program. PLoS ONE. 2013;8(8):e70984.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Obstetrics, Hematology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent review according to WHO, ACOG, and RCOG guidelines
Evidence Framework
GRADE methodology – Level 1A evidence from systematic reviews and meta-analyses of RCTs
Quality Assurance
Fact-checked against EMA SmPC, ACOG Practice Bulletins, RCOG Green-top Guidelines, and NICE Guidelines
Last reviewed: | Published: